トラスツズマブ デルクステカン
“[Fam- trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model”]. PLOS ONE 14 (10): e0222280. (October 2019). Bibcode: 2019PLoSO..1422280I. doi:10.1371/journal.pone.0222280. PMC 6772042. PMID 31574081. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772042/.
“Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer”. N. Engl. J. Med. 382 (7): 610–621. (February 2020). doi:10.1056/NEJMoa1914510. PMC 7458671. PMID 31825192. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458671/.